AlphAIAlphAI — Financial news for AI agents
benzinga.comOCT 142 min read$JNJ

These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results

Johnson & Johnson (JNJ) reported Q3 earnings of $2.59 per share, beating estimates, and raised full-year guidance. Sales grew 5.9% to $25.39 billion. Analysts cut price targets but maintained positive ratings. Shares rose 1.6% to $252.51.

Original reporting
benzinga.com
Published Oct 14, 2026, 5:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 5:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$JNJ
Neutral
high confidence
Mentioned
$JNJ
Relevance
9/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$JNJNeutralHigh
01

Why it matters

Earnings beat and guidance raise are primary catalysts; analyst target reductions add nuance but do not negate the positive earnings surprise.

02

Market read

The earnings beat and guidance lift provide a fresh trading signal for JNJ and may influence broader health‑care stocks.

03

What to watch

Potential headwinds from upcoming drug trial outcomes and macro‑economic pressures could dampen upside.

Relevance 9/10Novelty 8/10Timing: pre‑market today

Background

The article summarizes Johnson & Johnson's Q3 earnings release, including adjusted EPS, revenue, and updated full‑year guidance.

Company-level read

Ticker impact

$JNJNeutralHigh confidence
Context

Johnson & Johnson reported Q3 earnings beating estimates and raised full-year guidance, prompting a 1.6% share rise.

Expected impact

modest upward pressure as market prices in stronger guidance, tempered by target reductions

Evidence & confidence

The fresh earnings numbers and guidance lift are primary news; analyst target cuts reflect mixed sentiment but do not outweigh the beat.

Market effects

Sector

Healthcare sector may see modest rally as a large-cap pharma beats expectations.

Regional

U.S. markets could see slight upward bias in the health‑care index.

Global

Limited; impact confined to U.S. equities and pharma peers.

Counterpoint

What could challenge this read

Analyst target cuts suggest the market may have over‑reacted to the earnings beat.

Key entities

  • company
    Johnson & Johnson

    U.S. healthcare conglomerate reporting Q3 results.

Read at source← All news

StoryJohnson & Johnson reports Q3 results and raises 2026 guidance

Also covered by

6 outlets

Related articles

OCT 15
$JNJMedAI 8/10

Johnson & Johnson outlook: bull and bear cases after Q3 earnings

Johnson & Johnson (JNJ) reported Q3 adjusted EPS of $2.59, beating estimates. The company raised operational sales-growth guidance to 6.7%–7.1% and maintained $21B in free cash flow. Bulls highlight pipeline momentum and technical support, while bears point to margin compression and MedTech weakness. The stock trades at $259.80, with analysts' target upside at 9.8%.

investing.com2 min
OCT 14
$JNJMedAI 8/10

Johnson & Johnson CFO taps internal investment for medtech growth

Johnson & Johnson CFO Joseph Wolk stated the company will use internal investments to drive medtech growth, aiming for double-digit growth by 2030. Q3 medtech sales rose 2.5%, below expectations, but innovative medicine sales offset this. J&J reported $25B in net sales, up 6%, but net earnings dropped 96% YoY due to M&A and litigation costs. The company expects $101B-$101.4B in 2026 sales.

finance.yahoo.com2 min
OCT 14
$JNJHigh

Johnson & Johnson PR: Tylenol Recall to Talc Settlement

Johnson & Johnson (J&J) announced a $5.5B talc settlement on July 27, 2026, covering 76,000 ovarian cancer claims. The company expects to pay $3B in 2027, with the total potentially reaching $7B. J&J is also separating its orthopaedics business, DePuy Synthes, with a 2025 sales of $9.3B. Additionally, Kenvue, J&J's consumer health spinoff, was acquired by Kimberly-Clark for $48.7B in 2025. J&J's 2025 sales outlook was $93.5B to $93.9B.

everything-pr.com2 min
OCT 14
$JNJHighAI 8/10

J&J posts weak medical device sales, shares fall

Johnson & Johnson reported medical device sales of $8.6B, missing estimates of $8.71B, citing geopolitical issues. Shares fell 6%. CFO Joe Wolk attributed weakness to Middle East conflict, European austerity, and China pricing. The company raised its full-year sales forecast to $101.2B and adjusted earnings to $11.10 per share. Pharmaceutical sales rose 7.7% to $16.76B, with Tremfya sales up 68% to $2.4B.

manilatimes.net2 min
OCT 14
$JNJMed

JNJ Maintains by RBC Capital -- Price Target Lowered to $280

RBC Capital maintained an 'Outperform' rating for Johnson & Johnson (JNJ) but lowered its price target from $290 to $280. GuruFocus values JNJ at $194.40, suggesting a 28.2% overvaluation. Insiders have sold $67.8M in shares over the past three months, while analysts cite market conditions and competitive pressures for the cautious outlook.

gurufocus.com2 min